Research on factors predicting IVF outcomes in women with autoimmune diseases
Research of Predictive Factors of in Vitro Fertilization (IVF) Outcome in Women Affected by Autoimmune Disorders: From Biological Markers to Artificial Intelligence
Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06872294
This study is trying to find out what factors can help predict how well in vitro fertilization (IVF) works for women with autoimmune diseases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 43 Years |
| Sex | Female |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia (other) |
| Locations | 1 site (Pavia, Pavia) |
| Trial ID | NCT06872294 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify predictive factors that influence the outcomes of in vitro fertilization (IVF) in women suffering from autoimmune diseases. It focuses on understanding how various biological and clinical factors, including the health status of the women and the quality of gametes, affect the success rates of IVF. The study utilizes artificial intelligence to enhance the prediction of successful pregnancies by analyzing data related to the patients' conditions and treatment responses. By examining these factors, the research seeks to improve IVF outcomes for women with specific health challenges.
Who should consider this trial
Good fit: Ideal candidates for this study are women under 43 years old who are undergoing IVF with a fresh semen sample and have a sufficient count of progressive motile spermatozoa.
Not a fit: Patients with uterine abnormalities, chromosomal and genetic abnormalities, or positive serological tests for certain infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved IVF success rates for women with autoimmune diseases.
How similar studies have performed: While there have been studies exploring IVF outcomes in relation to various factors, the specific use of AI in this context is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women with age below 43 years old * IVF cycle with fresh semen sample that could be used * progressive motile spermatozoa expected count of minimum 1 million following density gradient purification on the day of oocyte pick up Exclusion Criteria: * Women with uterine abnormalities * Women with chromosomal and genetic abnormalities * Positivity to serological test (HCV, HBV, HIV, VDRL-TPHA)
Where this trial is running
Pavia, Pavia
- SSD Ostetricia e Ginecologia 2 - Fondazione IRCCS Policlinico San Matteo, Pavia — Pavia, Pavia, Italy (RECRUITING)
Study contacts
- Principal investigator: Claudia Omes, PhD — Fondazione IRCCS Policlinico San Matteo di Pavia
- Study coordinator: Claudia Omes, PhD
- Email: c.omes@smatteo.pv.it
- Phone: +390382503238
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Autoimmune Diseases